The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)

Kazutoshi Murakami, Jun Wada, Daisuke Ogawa, Chikage Sato Horiguchi, Tomoko Miyoshi, Motofumi Sasaki, Haruhito Adam Uchida, Yoshio Nakamura, Hirofumi Makino

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm2 in the TELMI group (p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm2, the change was not significant (p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalDiabetes and Vascular Disease Research
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Abdominal Fat
Intra-Abdominal Fat
Valsartan
Peroxisome Proliferator-Activated Receptors
Body Weight Changes
Waist Circumference
Therapeutics
Insulin Resistance
Fasting
Body Mass Index
Homeostasis
Fats
Tomography
Insulin
Glucose
telmisartan
Essential Hypertension

Keywords

  • Metabolic syndrome
  • PPARγ
  • telmisartan
  • valsartan
  • visceral adipose tissue

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{06df50c2dede40d58e78a1b38a66d662,
title = "The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO)",
abstract = "Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm2 in the TELMI group (p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm2, the change was not significant (p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan.",
keywords = "Metabolic syndrome, PPARγ, telmisartan, valsartan, visceral adipose tissue",
author = "Kazutoshi Murakami and Jun Wada and Daisuke Ogawa and Horiguchi, {Chikage Sato} and Tomoko Miyoshi and Motofumi Sasaki and Uchida, {Haruhito Adam} and Yoshio Nakamura and Hirofumi Makino",
year = "2013",
month = "1",
doi = "10.1177/1479164112444640",
language = "English",
volume = "10",
pages = "93--96",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension

T2 - Abdominal fat Depot Intervention Program of Okayama (ADIPO)

AU - Murakami, Kazutoshi

AU - Wada, Jun

AU - Ogawa, Daisuke

AU - Horiguchi, Chikage Sato

AU - Miyoshi, Tomoko

AU - Sasaki, Motofumi

AU - Uchida, Haruhito Adam

AU - Nakamura, Yoshio

AU - Makino, Hirofumi

PY - 2013/1

Y1 - 2013/1

N2 - Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm2 in the TELMI group (p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm2, the change was not significant (p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan.

AB - Telmisartan partially activates the peroxisome proliferator-activated receptor γ (PPARγ), which may ameliorate the accumulation of visceral adipose tissues and sensitise insulin action. Nineteen patients with essential hypertension and metabolic syndrome were randomly assigned to receive 40 mg of telmisartan (TELMI group) once daily or 80 mg of valsartan (VAL group) once daily for 24 weeks. The visceral fat area (VFA) measured by computed tomography (CT) was significantly reduced from 150.4±15.5 to 127.7±16.7 cm2 in the TELMI group (p=0.049). Although VFA was also reduced in the VAL group from 169.8±14.8 to 155.3±14.8 cm2, the change was not significant (p=0.173). There were no significant changes in body weight, body mass index (BMI), waist circumference, subdermal fat area (SFA), fasting plasma glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in comparison to the baseline and follow-up data in both groups. In conclusion, telmisartan may have a benefit in the reduction of visceral adipose tissues in comparison to valsartan.

KW - Metabolic syndrome

KW - PPARγ

KW - telmisartan

KW - valsartan

KW - visceral adipose tissue

UR - http://www.scopus.com/inward/record.url?scp=84871849211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871849211&partnerID=8YFLogxK

U2 - 10.1177/1479164112444640

DO - 10.1177/1479164112444640

M3 - Article

C2 - 22561230

AN - SCOPUS:84871849211

VL - 10

SP - 93

EP - 96

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 1

ER -